SLC29A1 and pancreatic neoplasm: concluded that most cell lines take up gemcitabine via SLC29A1 instead of SLC28A1, which is expressed in human pancreatic cancer at high levels, and that the expression of SLC28A1 and SLC29A1 may increase the sensitivity of pancreatic cancer cells to gemcitabine.102